Skip to main content

Oral administration of drugs with low bioavailability

These nanoparticles have demonstrated to be highly bioadhesive which allows to increase biavailability by obtaining a low toxic effect and high efficacy.


INP12 are nanoparticles with encapsulated paclitaxel as a model of low bioavailable drug. These nanoparticles have demonstrated to increase bioavailability in preclinical studies, obtaining very low toxicity and higher efficacy than its reference treatment (intravenous paclitaxel: Taxol®) when administered by oral route. Phase I clinical trial has been already approved by competent authorities and it will start in 2021.

INP12 aims to be a platform to develop new products in the future that currently cannot be administered orally due to their low bioavailability.

Adjuvant capacity by mucosal administration

These nanoparticles have demonstrated to improve antigen presentation to immunocompetent cells by mucosal administration (oral, intranasal, pulmonary…).

By mimicking the size of microorganisms (bacteria and viruses), these nanocarriers can be taken up by the immune cells and modulate their responses. This skill can be applied to develop vaccines or immunotherapy treatments for allergy diseases.


INP20 are nanoparticles with encapsulated peanut extract as a food allergen. These nanoparticles have demonstrated to be completely innocuous in animal studies when administered by oral route and now, a phase I clinical study is being developed to evaluate safety in peanut allergic patients.

INP20 aims to be a platform to develop immunotherapeutic products to treat other food allergies.

INP30 are nanoparticles with encapsulated inactivated SARS-CoV2. Preclinical studies are being developed to demonstrate their immunogenic effect.

INP30 aims to be a platform to develop oral vaccines based on other viruses and bacteria.